Selecting an optimal antibody for antibody-drug conjugate therapy: Internalization and intracellular localization

Methods in Molecular Biology

Volumn 1045, Issue , 2013, Pages 41-49

  Harper, Jay ^a   Mao, Shenlan ^a   Strout, Patrick ^a   Kamal, Adeela ^a  

^a MEDIMMUNE   (United States)

Author keywords

Antibodies; Antibody drug conjugate; Confocal microscopy; Flow cytometry; Internalization

Indexed keywords

ANTIBODY; ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; CYTOTOXIC AGENT; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; ASSAY; CELL VIABILITY; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CYTOTOXICITY; DRUG CONJUGATION; FLOW CYTOMETRY; INTERNALIZATION; LYSOSOME; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 84934444193     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-541-5_3     Document Type: Article

References (9)

1. Ducry L, Stump B (2010) Antibody-drug conjugates: Linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem 21:5-13
2. Katz J, Janik JE, Younes A (2011) Brentuximab vedotin (SGN-35). Clin Cancer Res 17: 6428-6436
3. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Dieras V, Guardino E, Fang L, LuMW, Olsen S, Blackwell K (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783-1791
4. Alley SC, Okeley NM, Senter PD (2010) Antibody-drug conjugates: Targeted drug delivery for cancer. Curr Opin Chem Biol 14:529-537
5. Polson AG, Calemine-Fanaux J, Chan P, Chang W, Christensen E, Clark S, de Sauvage FJ, Eaton D, Elkins K, Elliot JM, Frantz G, Fuji RN, Gray A,Harden K, Ingle GS, Kljavin NM, Koeppen H, Nelson C, Prabju S, Raab H, Ross S, Stephan J-P, Scales SJ, Spencer SD, Vandlen R,Wranik B, Yu S-F, Zheng B, Ebens A (2009) Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: Target and linkerdrug selection. Cancer Res 69:2358-2364
6. Carter PJ, Senter PD (2008) Antibody-drug conjugates for cancer therapy. Cancer J 14:154-169
7. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blattler WA, Lambert JM, Chari RVJ, Lutz RJ, Wong WLT, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, and antibody-cytotoxic drug conjugate. Cancer Res 68:9280-9290
8. Hommelgaard AM, Lerdrup M, van Deurs B (2004) Association with membrane protrusions makes ErbB2 an internalization-resistant receptor. Mol Biol Cell 15:1557-1567
9. Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, Weiner LM, Marks JD, Adams GP et al (2011) Influence of affinity and antigen internalization on the uptake and penetration of anti-HER2 antibodies in solid tumors. Cancer Res 71:2250-2259